Leukemic fitness predicts treatment-free remission and guides adaptive therapy in chronic myeloid leukemia
Chronic myeloid leukemia is controlled by tyrosine kinase inhibitors, yet only about half of well-responding patients who stop therapy remain in long-term remission, and currently it cannot be predicted who will relapse. Mechanistic models reproduce both outcomes but rely on many parameters and longitudinal immune measurements, limiting clinical use. Here we derive a minimal two-equation model in…
We haven't written up this one. bioRxiv has the full story — the link below goes straight to it.
